Antonio Llombart‐Cussac

Research interests

Publications

• Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2410858

• Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

  Annals of Oncology · 2024 · 10.1016/j.annonc.2024.04.013

• Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

  Annals of Oncology · 2024 · 10.1016/j.annonc.2024.04.013

• Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

  Neuro-Oncology · 2022 · 10.1093/neuonc/noac144

• Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

  Neuro-Oncology · 2022 · 10.1093/neuonc/noac144

• Enhancing global access to cancer medicines

  CA A Cancer Journal for Clinicians · 2020 · 10.3322/caac.21597

• Enhancing global access to cancer medicines

  CA A Cancer Journal for Clinicians · 2020 · 10.3322/caac.21597

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30786-7

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30786-7

• The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

  JAMA Oncology · 2019 · https://doi.org/10.1001/jamaoncol.2019.4782

• HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

  JNCI Journal of the National Cancer Institute · 2019 · https://doi.org/10.1093/jnci/djz042

• Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis

  JNCI Journal of the National Cancer Institute · 2018 · https://doi.org/10.1093/jnci/djy018

• HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30021-9

• MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2017.73.7585

• Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.61.5831

• Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.61.5831

• Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

  Breast Cancer Research and Treatment · 2012 · 10.1007/s10549-012-2192-4

• Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

  Annals of Oncology · 2012 · 10.1093/annonc/mds277

• Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life

  Supportive Care in Cancer · 2012 · 10.1007/s00520-012-1448-1

• Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

  Breast Cancer Research and Treatment · 2012 · 10.1007/s10549-012-2192-4

• Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life

  Supportive Care in Cancer · 2012 · 10.1007/s00520-012-1448-1

• Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

  Annals of Oncology · 2010 · 10.1093/annonc/mdq217

• Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.21.1136

• Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.19.2567

• Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.19.2567

• Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.11.9362

• Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.12.9437

• A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2006.09.6578

• A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2006.09.6578

• Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy

  Annals of Oncology · 2006 · 10.1093/annonc/mdj134

• Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy

  Annals of Oncology · 2006 · 10.1093/annonc/mdj134

• Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.

  PubMed · 2003

• Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.

  PubMed · 2003

• Prognostic Factors in Primary Breast Sarcomas: A Series of Patients With Long-Term Follow-Up

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.06.080

• Prognostic Factors in Primary Breast Sarcomas: A Series of Patients With Long-Term Follow-Up

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.06.080

• Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

  Annals of Oncology · 2001 · 10.1023/a:1013128213451

Current projects

No projects listed.